DDrare: Database of Drug Development for Rare Diseases

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群
［臨床試験数：20，薬物数：26（DrugBank：10），標的遺伝子数：12，標的パスウェイ数：90］

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = APD334; Adalimumab; CICLOSPORIN; Canakinumab; Ciclosporin; Cosentyx; Cosentyx®; EU/1/14/980/002; EU/1/14/980/003; Gelatin; Gevokizumab; Gevokizumab open-label; Humira; IFX-1; Infliximab; Ixekizumab; Neoral Oral Solution; Neoral soft gelatin capsules; PREDNISOLONE; Prednisolone; Secukinumab; Secukinumab 150 mg (2 injections per dose; Stelara; USTEKINUMAB; Ustekinumab; Xilonix

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03137160 (ClinicalTrials.gov)	May 4, 2017	27/4/2017	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Biological: Ixekizumab	Ohio State University	Eli Lilly and Company	Completed	18 Years	N/A	All	5	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03137160
(ClinicalTrials.gov)

May 4, 2017

27/4/2017

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

Biological: Ixekizumab

Ohio State University

Eli Lilly and Company

Completed

18 Years

N/A

All

Phase 2

United States